Text this: A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

 __   __   __   __   __   _      ___      ____    
 \ \\/ //  \ \\/ // | || | ||   / _ \\   |  _ \\  
  \   //    \ ` //  | '--' ||  / //\ \\  | |_| || 
  / . \\     | ||   | .--. || |  ___  || | .  //  
 /_//\_\\    |_||   |_|| |_|| |_||  |_|| |_|\_\\  
 `-`  --`    `-`'   `-`  `-`  `-`   `-`  `-` --`